Bausch + Lomb Turns To Familiar Face As CEO, Brent Saunders

Saunders will oversee the consumer health, pharma and medtech eye health and vision care specialist, returning to where he got his start as a chief executive before earning a reputation as one of industry’s biggest dealmakers.

• Source: Shutterstock

Health sciences industry veteran Brent Saunders is returning to a company he knows particularly well: Bausch + Lomb Inc., the consumer health, pharma and medtech eye health and vision care specialist where he first cut his teeth as a CEO in 2010.

More from Leadership

People On The Move: Appointments At Pharma Deutschland, MHRA, Futura

 
• By 

A round-up of the latest industry moves in Europe: Pharma Deutschland elects board of new Brussels operation; MHRA's new CEO gets to work; Futura names non-executive director.

Government Pulls ‘For Sale’ Signs From US FDA’s White Oak Campus

 
• By 

The General Services Administration’s updated list of “assets identified for accelerated disposition” does not include any buildings at the agency’s headquarters in White Oak, MD after its original list of “non-core” government properties for disposal had more than half the buildings on campus.

People On The Move: Appointments At PAGB, Activ’Inside, EMA

 
• By 

Round up of the latest appointments: PAGB names vice presidents; Activ'Inside gets first US head; EMA elects management board chair.

Will Martin Makary Bring Calm To US FDA As Commissioner During Turbulent Times?

 

Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.

More from HBW Insight

People On The Move: Appointments At Pharma Deutschland, MHRA, Futura

 
• By 

A round-up of the latest industry moves in Europe: Pharma Deutschland elects board of new Brussels operation; MHRA's new CEO gets to work; Futura names non-executive director.

Marketplace Results After FDA OTC Monograph Overhaul Rely On OMUFA Reauthorization

 

“If this doesn’t get reauthorized, look at the number of the ingredients out there, the number of products, what would happen all those products out there for the consumer, on that shelf, in the drugstore or someplace?” says Rep. Bob Latta during House hearing.

Democrats Torch Trump’s HHS Layoffs During House Hearing On OMUFA Reauthorization

 

Energy and Commerce Health Subcommittee Democrats focus on criticizing HHS Secretary Kennedy’s RIF announcement, including 3,500 FDA jobs among cuts across HHS agencies. “If we reauthorize it, will it continue?” Texas representative Lizzie Fletcher asks of OMUFA.